Clinical Trial Update: Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of DEXTENZA 0.4 mg intracanalicular insert after cataract surgery has completed. The study assessed outcomes re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Chamber Inflammation
• Corneal Edema
• Cystoid Macular Edema

Drugs mentioned

• Dextenza (Dexamethasone)

Snippet

Sponsor: Nicole Fram M.D. | Conditions: Corneal Edema, Corneal Defect | Phase 4 | Status: COMPLETED